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Changes in the plasma proteome
at asymptomatic and symptomatic
stages of autosomal dominant
Alzheimer’s disease
Julia Muenchhoff 1, Anne Poljak1,2,3, Anbupalam Thalamuthu1, Veer B. Gupta4,5,
Pratishtha Chatterjee4,5,6, Mark Raftery2, Colin L. Masters7, John C. Morris8,9,10,
Randall J. Bateman8,9, Anne M. Fagan8,9, Ralph N. Martins4,5,6 & Perminder S. Sachdev1,11
The autosomal dominant form of Alzheimer’s disease (ADAD) is far less prevalent than late onset
Alzheimer’s disease (LOAD), but enables well-informed prospective studies, since symptom onset is
near certain and age of onset is predictable. Our aim was to discover plasma proteins associated with
early AD pathology by investigating plasma protein changes at the asymptomatic and symptomatic
stages of ADAD. Eighty-one proteins were compared across asymptomatic mutation carriers (aMC,
n = 15), symptomatic mutation carriers (sMC, n = 8) and related noncarriers (NC, n = 12). Proteins were
also tested for associations with cognitive measures, brain amyloid deposition and glucose metabolism.
Fewer changes were observed at the asymptomatic than symptomatic stage with seven and 16 proteins
altered significantly in aMC and sMC, respectively. This included complement components C3, C5,
C6, apolipoproteins A-I, A-IV, C-I and M, histidine-rich glycoprotein, heparin cofactor II and attractin,
which are involved in inflammation, lipid metabolism and vascular health. Proteins involved in lipid
metabolism differed only at the symptomatic stage, whereas changes in inflammation and vascular
health were evident at asymptomatic and symptomatic stages. Due to increasing evidence supporting
the usefulness of ADAD as a model for LOAD, these proteins warrant further investigation into their
potential association with early stages of LOAD.
Due to the ageing of the population in most countries, dementia is a rapidly growing problem with cases predicted to rise to about 115 million worldwide by 20501. The most common cause of dementia is Alzheimer’s
disease (AD), for which there is at present no cure. It is hypothesised that several decades-long asymptomatic
pathological processes lead up to the clinical manifestation of AD2, however, these early pathological processes
are still poorly defined.
Identification of the processes and associated biochemical changes leading up to symptomatic AD is a difficult
task as it cannot be predicted who will develop late onset AD (LOAD) in the future. By contrast, the autosomal dominant form of AD (ADAD) has near absolute certainty of onset in mutation carriers (MC) and the age
at onset (AAO) is also predictable based on family history3. This enables well-informed prospective studies to
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identify early changes associated with AD pathology. Furthermore, the relatively young age of ADAD patients
minimises age-related changes and co-morbidities, which can confound studies in older adults.
ADAD is caused by mutations that effect alterations in amyloid precursor protein (APP) processing. Mutations
have been identified in three genes [APP, NCBI Entrez Gene 351, presenilin 1 (PSEN1, NCBI Entrez Gene 5663),
or presenilin 2 (PSEN2, NCBI Entrez Gene 5664)] and provide a defined change in biochemical pathways that can
be studied. Less than 1% of all AD cases are attributed to ADAD, but increasing evidence suggests that the clinical
and neuropathological features of ADAD and LOAD are similar, encouraging the use of ADAD as a model for
AD in general2,4,5.
Cerebrospinal fluid (CSF) has been the major focus for tracking biochemical changes related to AD. Several
studies measured CSF and plasma amyloid-β (Aβ) and tau species as well as CSF proteins in ADAD MC2,4,10–13,
however, to the best of our knowledge, discovery-based proteomics have not yet been applied to blood samples
from ADAD MC. Blood is readily accessible and routinely used in tracking onset and progression of a variety of
diseases involving peripheral organs. Approximately 500 mL CSF are absorbed into the blood daily, making it a
credible resource for studying brain disorders. It is also likely that the blood-brain barrier is compromised early
on in AD6, potentially allowing brain-associated molecules to enter the blood stream. There is mounting evidence
to indicate that protein (and lipid) changes in the periphery reflect the asymptomatic, prodromal and symptomatic stages of LOAD7–9, but how this compares to plasma protein changes in the asymptomatic and symptomatic
stages of ADAD is currently unknown.
In this pilot study on a small number of samples, we used the unbiased comparative proteomics technique of
isobaric tags for relative and absolute quantitation (iTRAQ) to compare the plasma protein profiles of ADAD MC
at asymptomatic and symptomatic stages with related noncarriers (NC) with the aim to explore disease mechanisms and discover proteins associated with early stages of AD pathology. Each of the 81 proteins quantified
was tested for associations with cognitive measures, brain amyloid deposition, glucose metabolism and brain
volumetrics. Proteins differentially abundant in MC and NC and associated with the measures above indicate the
pathways that are affected by AD pathology at the asymptomatic and symptomatic stages.

Results

Cohort characteristics.

Participant characteristics are presented in Table 1. The mutation types of the 35
participants included various PSEN1 mutations (ΔE9, Q222H, H163R, I436V, L271V, M233T, S169L, S170F
and S290C) from 11 pedigrees and the APPE693Q (Dutch mutation) from one pedigree. The participants were
grouped according to cognitive and mutation status into NC (n = 12), aMC (CDR score of 0, n = 15) and sMC
(CDR score ≥0.5, n = 8). One participant in the NC group had a CDR of 0.5 due to severe depression. sMC were
entirely comprised of PSEN1 MC. The MMSE ranged from 23 to 30 for NC, 26 to 30 for asymptomatic and 12 to
26 for symptomatic MC. PiB PET data was available for ten NC, 12 aMC and six sMC. PiB PET SUVRs ranged
from 0.43 to 0.64 for NC, 0.48 to 2.05 for aMC and 0.45 to 2.72 for sMC. Using a cut off of ≥0.75, none, six and six
participants were positive for fibrillar amyloid in the precuneus and/or caudate nucleus in the NC, asymptomatic
and symptomatic MC groups, respectively.

Quantitation of plasma proteins using iTRAQ.

iTRAQ enables unbiased quantitative comparison of
proteins present in multiple samples by labelling of peptides with isobaric stable isotope tags that fragment upon
collision-induced dissociation into reporter ions used for quantitation. A maximum of eight tags are available
so that up to eight samples can be multiplexed and analysed at the same time, avoiding run-to-run variation. If
more than eight samples are to be analysed, several multiplex experiments are performed, each containing the
same reference standard to enable relative quantitation of proteins across all experiments. Here six 8-plex iTRAQ
experiments were performed for analysis of the 35 immunodepleted plasma samples. As reference, a pool of
plasma samples from all NC was used. Therefore, each iTRAQ multiplex experiment enabled the identification
and quantitation of seven protein samples relative to the pooled reference standard.
Supplementary Table S1 summarises the results of the six iTRAQ multiplex experiments, including the number of proteins identified at a local FDR of 1%. Eighty-one proteins were quantified across all 35 plasma samples
and used in the statistical analyses. Their relative abundances are given in Supplementary Table S2. The ratio represents the abundance of each protein relative to the same protein in the reference pool that was included in all of
the multiplex iTRAQ experiments. The ratio value is used to compare each individual in the NC, aMC and sMC
groups (cf to using the reference pool itself as baseline for comparisons). Only human proteins with a minimum
unused score of 1.3 (≥95% confidence in correct sequence identification) and at least two distinct peptides for
protein identification were included.

Plasma proteins differentially abundant in asymptomatic carriers of PSEN1 and Dutch mutations
and NC. Using a linear model with age, gender, APOE ε4 status, EYO, mutation type and status (i.e. NC, PSEN1

and Dutch mutation groupings) as covariates, we compared the plasma protein profiles of asymptomatic carriers
of PSEN1 and Dutch mutations to investigate potential differences in protein expression in these phenotypically
different mutation types. Eight proteins were found to differ significantly between these groups (Supplementary
Fig. S1), namely complement C4-A, zinc-α-2-glycoprotein, hemopexin, N-acetylmuramoyl-L-alanine amidase, α-2-antiplasmin, apolipoprotein L1, C1 inhibitor and inter-α-trypsin inhibitor heavy chain H2 (ITIH2).
Comparisons of asymptomatic PSEN1 MC and NC as well as asymptomatic Dutch MC and NC identified 16 and
14 proteins as differentially abundant between these groups, respectively, with three proteins (fibronectin, complement C3 and α-2-antiplasmin) common to both comparisons (Supplementary Table S3). The effect size ranged
from −1.23 for apolipoprotein L1 to 1.64 for complement C4-A. However, the sample numbers of PSEN1 and Dutch
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Characteristic

NC (n = 12) Asymptomatic MC (n = 15) Symptomatic MC (n = 8)
44.0 (10.8)

Age, years (SD)

35.2 (10.7)

38.8 (9.4)a

Parental age at onset, years (SD)

50.3 (4.1)

47.3 (7.3)

46.6 (15.1)

–

−8.5 (7.1)a

−2.6 (6.6)a

Female, n (%)

9 (75.0)

11 (73.3)

5 (62.5)

APOE ε4+, n (%)

2 (16.7)

4 (26.7)

3 (37.5)a

PSEN1

2

6

8

APPE693Q (Dutch mutation)

10

9

–

11 (91.7)

15 (100)

–

1 (8.3)

–

5 (62.5)

1

–

–

2 (25.0)

2

–

–

1 (12.5)

3

–

–

–

27.8 (2.4)

28.0 (1.4)

20.6 (6.2)a

Immediate recall (LM-IA score)

14.5 (5.4)

16.1 (4.1)

5.0 (6.0)a

Delayed recall (LM-IIA score)

13.4 (5.8)

13.9 (5.4)

3.6 (5.7)a

2.4 (0.1)

2.4 (0.2)

2.0 (0.2)a

Precuneus

2.6 (0.2)

2.6 (0.2)a

2.0 (0.2)a

Caudate nucleus

1.9 (0.1)

1.9 (0.2)

a

1.8 (0.1)a

Precuneus

0.6 (0.04)

0.9 (0.4)a

2.0 (0.8)a

Caudate nucleus

0.5 (0.1)

0.8 (0.5)

1.7 (0.8)a

0 (0)

6 (50.0)

Participant’s estimated years to onset, years (SD)

Family mutations, n

Clinical Dementia Rating score, n (%)
0
0.5

Mini Mental State Exam score (SD)
Episodic memory

Average precuneus thickness, mm (SD)
Glucose metabolism, FDG PET SUVR (SD)c

Aβdeposition, PiB PET SUVR (SD)

PiB positive, n (%)

c

a

6 (100.0)

Table 1. Participant characteristics. APOE ε4+, at least one apolipoprotein E ε4 allele present; FDG PET
SUVR, fluorodeoxyglucose (18F) positron emission tomography standard uptake value ratio; PiB PET SUVR,
Pittsburgh compound B positron emission tomography standard uptake value ratio; PiB positive, PiB PET
SUVR in the precuneus and/or caudate nucleus is ≥0.75. ap < 0.05 compared with NC. bNormalised to
brainstem.

aMC are very small (PSEN1 n =  6, Dutch n = 9) and all Dutch MC are from the same family. Hence, this has to be
considered an exploratory analysis that requires replication in a larger sample.

Plasma proteins differentially abundant in NC, aMC and sMC. Using a linear model with age, gender, APOE ε4 status, EYO, mutation and diagnostic status (i.e. NC, aMC and sMC groupings) as covariates, we
compared the plasma protein profiles of NC, aMC and sMC. Eighteen proteins differed significantly (q <  0.05)
in the global test of abundance in the three groups (Table 2). The effect size ranged from −0.85 for histidine-rich
glycoprotein (HRG) to 0.74 for thyroxine-binding globulin (TBG). In total, six of the proteins identified here
were also differentially abundant in the above comparison of NC with asymptomatic carriers of PSEN1 or Dutch
mutations (Supplementary Table S3) [lumican, TBG, complement components C3 and C6, heparin cofactor II
(HCII) and attractin (ATRN)].
Group comparisons were performed to compare the levels of these 18 proteins between NC and aMC as well
as NC and sMC. Levels of complement components C3, C5, C6, protein α-1-microglobulin/bikunin precursor,
HRG, HCII and ATRN differed significantly (p < 0.025) between NC and aMC (Fig. 1). Except for ATRN, the
same proteins also differed significantly between NC and sMC, together with the additional proteins lumican,
α-1-antichymotrypsin (ACT), TBG, C4b-binding protein α chain, α-2-HS-glycoprotein (AHSG), ceruloplasmin,
apolipoproteins A-I (ApoA1), A-IV (ApoA4), C-I (ApoC1) and M (ApoM) (Fig. 1). ITIH2 did not differ significantly in the group comparisons (Fig. 1). The majority of these proteins are involved in inflammation, hemostasis
and lipid metabolism (Table 2).
Plasma proteins associated with cognition and neuroimaging markers. The 81 proteins quantified
in plasma from all participants were tested for their associations with cognitive function (MMSE score), episodic
memory (LM-IA and LM-IIA scores), precuneus thickness (MRI), glucose metabolism (FDG PET) and amyloid
deposition (PiB PET) in the precuneus and the caudate nucleus. The precuneus and caudate nucleus were chosen
for analyses, as they are known to show early amyloid deposition in ADAD2. Thirty-five proteins were significantly associated with at least one of these measures (Fig. 2 and Supplementary Tables S4–S7), including nine
proteins that significantly differed in abundance among aMC, sMC and NC groups (Table 2): ApoM and TBG
were associated with glucose metabolism in the precuneus, whereas C6, ATRN, HRG and lumican were associated with glucose metabolism in the caudate nucleus. ApoA1 was the only protein of the nine to be associated
Scientific Reports | 6:29078 | DOI: 10.1038/srep29078
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Biological process

Protein (UniProt accession, gene symbol)

Protein
abbreviation

β
coefficient

Standard
error

q-value

Complement system

Complement component C6 (P13671, C6)

C6

−0.35

0.07

1.31 ×  10−5

Complement system

Complement component C5 (P01031, C5)

C5

0.46

0.11

3.24 ×  10−5

Complement system

Complement component C3 (P01024, C3)

C3

0.52

0.18

0.0160

Complement system

C4b-binding protein αchain (P04003, C4BPA)

C4BPA

0.38

0.14

0.0272

Inflammatory response

Attractin (O75882, ATRN)

ATRN

−0.84

0.20

3.24 ×  10−4

Acute phase response

α-1-antichymotrypsin (P01011, SERPINA3)

ACT

−0.32

0.12

0.0341

Acute phase response,
mineral balance

α-2-HS-glycoprotein (P02765, AHSG)

AHSG

0.27

0.09

0.0093

Hyaluronan metabolism,
inflammation

Inter-α-trypsin inhibitor heavy chain H2 (P19823,
ITIH2)

ITIH2

0.38

0.16

0.0490

Hemostasis, acute phase

Histidine-rich glycoprotein (P04196, HRG)

HRG

−0.85

0.20

3.24 × 10−4

Hemostasis

Heparin cofactor II (P05546, SERPIND1)

HCII

0.41

0.13

0.0070

Apolipoprotein C-1 (P02654, APOC1)

ApoC1

−0.30

0.07

3.63 × 10−4

Lipid metabolism

Apolipoprotein A-I (P02647, APOA1)

ApoA1

−0.29

0.09

0.0044

Lipid metabolism

Apolipoprotein A-IV (P06727, APOA4)

ApoA4

−0.36

0.11

0.0071

Lipid metabolism

Apolipoprotein M (O95445, APOM)

ApoM

−0.46

0.19

0.0414

Protease inhibitor

Protein α-1-microglobulin/bikunin precursor
(P02760, AMBP)

AMBP

0.27

0.08

0.0044

Lumican (P51884, LUM)

LUM

0.37

0.12

0.0107

Iron homeostasis

Ceruloplasmin (P00450, CP)

CP

−0.23

0.09

0.0386

Thyroid hormone
transport

Thyroxine-binding globulin (P05543, SERPINA7)

TBG

0.74

0.30

0.0386

Lipid metabolism

Collagen fibril
organisation

Table 2. Proteins that differed significantly in abundance between NC, aMC and sMC groups. A linear
model including age, gender, APOE ε4 status, estimated years from expected symptom onset (EYO), mutation and
diagnostic status (i.e. NC, aMC and sMC groupings) as covariates was used. Proteins with a q value of <0.05 are
considered significant. The abundance ratios for these proteins are given in Fig. 1.

with precuneus thickness. TBG and HCII were associated with amyloid deposition in the precuneus and caudate
nucleus, respectively. Regarding cognitive measures, lumican was associated with MMSE score, and AHSG with
episodic memory (LM-IIA score).
The protein with the most significant associations was complement component C4-A (C4A), being linked to
two (MMSE and LM-IA) of the three cognitive measures and four (precuneus thickness, glucose metabolism in
the precuneus, amyloid deposition in the precuneus and caudate nucleus) of the five neuroimaging measures.
C4b-binding protein βchain was strongly associated with both episodic memory scores.
The strongest and most consistent associations for amyloid deposition in the precuneus and caudate nucleus
were with C4A, tetranectin, kininogen-1 and Vitamin K-dependent protein S.

Validation of iTRAQ proteomics using orthogonal method. To verify the quantitative data obtained

by iTRAQ proteomics, levels of HCII were quantified by enzyme-linked immunosorbent assay (ELISA) in the low
abundance protein fractions derived from all plasma samples and used in the iTRAQ experiments, including the
NC reference masterpool. For comparison with the iTRAQ data, results were expressed as the ratio of μg HCII
per mg low abundance protein relative to the NC pool (Supplementary Table S8). Quantitation by both methods
corresponded well with a correlation coefficient (r) of 0.58 (p = 0.0003), however, the statistically significant difference in HCII levels between NC and aMC as well as NC and sMC groups was not replicated.

Protein network analysis. The 18 proteins that were differentially abundant in NC and MC at asymptomatic and symptomatic stages were analysed for molecular functions, biological processes and KEGG pathways
that might be enriched against the background of the 81 proteins quantified. However, none of the molecular
functions, biological processes or pathways were significantly enriched.
In a network analysis, 14 proteins formed a network associated with AD, vascular disease and inflammatory
response (Fig. 3). ApoC1 and C6 did not link to any proteins but instead to the disease processes and functions in
the network. ITIH2 and ATRN had no links of any kind to the network, but their respective interactions are also
shown in Fig. 3. ITIH2 is connected to a five-protein network related to hyaluronic acid binding.

Discussion

This preliminary study using a small number of samples identified proteins that were potentially differentially
abundant in plasma from asymptomatic and symptomatic carriers of mutations causing ADAD compared to NC.
Potential differences in PSEN1 and Dutch mutation types were also investigated. In addition, proteins were tested
for association with cognition and neuroimaging markers in this cohort. To the best of our knowledge this is the
first discovery proteomics study using plasma from ADAD MC.
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Figure 1. Ratios of differentially abundant proteins. Mean ratios and standard deviations of plasma proteins
from noncarriers (NC), asymptomatic (aMC) and symptomatic mutation carriers (sMC) relative to reference
masterpool as quantified by iTRAQ. All 18 proteins differed significantly in abundance in a global comparison
of NC, aMC and sMC groups (Table 2). Ratios that significantly differed from the NC group in pairwise
comparisons are marked with asterisks (*p < 0.05/2 compared to NC; **p < 0.01/2 compared to NC). ApoA1,
Apolipoprotein A-I; ApoM, apolipoprotein M; C3, complement component C3; C5, complement component
C5; C6, complement component C6; C4BPA, C4-b binding protein αchain; ACT, α-1-antichymotrypsin;
TBG, thyroxine-binding globulin; HCII, heparin cofactor II; LUM, lumican; ATRN, attractin; AMBP, protein
α-1-microglobulin/bikunin precursor; ApoA4, apolipoprotein A-IV; ApoC1, apolipoprotein C-I; HRG,
histidine-rich glycoprotein; AHSG, α-2-HS-glycoprotein; CP, ceruloplasmin; ITIH2, inter-α-trypsin inhibitor
heavy chain H2.

Plasma protein profiles of asymptomatic PSEN1 and Dutch mutation carriers. Nine of the aMC
in this study carry the Dutch mutation, which is phenotypically distinct from other PSEN1 or APP mutations in
that it features more severe cerebral amyloid angiopathy (CAA) and cerebral haemorrhage, but fewer plaques
and neurofibrillary tangles14,15. Therefore, we investigated differences in the plasma protein profiles of asymptomatic carriers of PSEN1 and Dutch mutations, hypothesising that Dutch MC would show pronounced changes
in proteins relating to vascular health. The eight proteins that were differentially abundant between PSEN1 and
Dutch MC are mainly involved in the immune response, inflammation and transport of heme and lipids, but
α-2-antiplasmin functions in vascular health as a serine protease inhibitor specific for plasmin, thereby regulating fibrinolysis. Homozygous deficiency in α-2-antiplasmin results in uncontrolled fibrinolysis and subsequent
severe haemorrhagic tendencies16. Hemopexin and apolipoprotein L1 have tentative links to vascular health, but
further studies are needed to confirm these proposed roles. Hemopexin has been suggested to control heme-iron
recovery within the brain, where excess heme is associated with intracerebral or subarachnoid hemorrhages
and ischemia17. Apolipoprotein L1 has been linked to atherosclerosis18. Interestingly, α-2-antiplasmin was also
Scientific Reports | 6:29078 | DOI: 10.1038/srep29078
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Figure 2. Heat map of proteins associated with cognition and neuroimaging measures. The heat map
shows proteins that were significantly associated with at least one of eight outcomes, namely cognitive function
represented by MMSE score, episodic memory represented by LM-IA and LM-IIA scores, average precuneus
thickness (PC thick), glucose metabolism in the precuneus (FDG PC) and caudate nucleus (FDG CN) and
amyloid deposition in the precuneus (PiB PC) and caudate nucleus (PiB CN). Associations marked with **
were found to be significant with a Bonferroni corrected p value of < 0.05/81. Colour represents scaled β values
with red indicating positive associations and blue negative associations. The actual values for β coefficients,
standard errors and p-values are given in Table S4. A1BG, α-1B-glycoprotein; AHSG, α-2-HS-glycoprotein;
ApoA1, Apolipoprotein A-I; ApoE, apolipoprotein E; ApoM, apolipoprotein M; ATRN, attractin; AZGP1,
zinc-α-2-glycoprotein; C1R, complement C1r subcomponent; C2, complement C2; C4A, complement C4-A;
C4BPB, C4-b binding protein βchain; C6, complement component C6; C8B, complement component C8; CFB,
complement factor B; CFI, complement factor I; TN, tetranectin; F12, coagulation factor XII; FGB, fibrinogen β
chain; FN1, fibronectin; HBB, haemoglobin subunit β; HRG, histidine-rich glycoprotein; IGHG3, Ig γ-3 chain C
region; IGHM, Ig μchain C region; KNG1, kininogen; KNG1-LW, low molecular weight isoform of kininogen;
LUM, lumican; KLKB1, plasma kallikrein; PROS1, Vitamin K-dependent protein S; SERPINA4, kallistatin;
TBG, thyroxine-binding globulin; HCII, heparin cofactor II; SERPINF1, pigment epithelium-derived factor;
SERPINF2, α-2-antiplasmin; C1Inh, plasma protease C1 inhibitor; VTN, vitronectin. The heat map was
generated using the R package gplots.
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Figure 3. Protein network (IPA) of the proteins differentially abundant in NC, aMC and sMC groups.
IPA analysis of the differentially abundant proteins (denoted by their gene names, refer to Table 2), which are
coloured in red (increased abundance in sMC vs NC), blue (decreased abundance in sMC vs NC) and grey
(differentially abundant in NC, aMC and sMC but not in sMC vs NC comparison). Prevalent functions and
disease processes related to the proteins are indicated in the network by purple and green symbols, respectively.

differentially abundant in both PSEN1 aMC to NC as well as Dutch aMC to NC comparisons, whereas hemopexin
and apolipoprotein L1 were differentially abundant in PSEN1 aMC relative to NC, indicating vascular involvement is not exclusive to the Dutch mutation.
Comparisons of asymptomatic PSEN1 MC to NC as well as Dutch MC to NC showed limited overlap of proteins, which may relate to the phenotypic differences resulting from these two different gene mutations. However,
both groups showed similar alterations relative to the NC group in proteins related to vascular health. Four proteins with vascular functions were deregulated in each of the PSEN1 and Dutch mutation groups and two of
these, fibronectin and α-2-antiplasmin, were common to both groups. Kallikrein and kininogen-1, deregulated
in PSEN1 MC relative to NC, as well as kallistatin, deregulated in Dutch MC relative to NC, are all part of the
kallikrein-kinin system. Similarly, the biological processes indicated by the other proteins that were differentially
abundant in PSEN1 aMC to NC and Dutch aMC to NC comparisons were alike, suggesting that subtle changes to
specific proteins may differentiate these genetic dementia variants, but within the framework of similar biological
processes. However, due to the small sample size of both groups and the relatedness of all Dutch MC in this study,
this comparison is underpowered from a statistical point of view, and the conclusions will need to be confirmed
by future studies, which should include higher sample and pedigree numbers.
Although the above analysis revealed potential subtle differences in the protein profile of PSEN1 and Dutch
aMC, it also showed the common themes of inflammation and vascular changes in both these groups. Both mutation types share the underlying pathology of an altered Aβmetabolism, resulting in CAA and plaques albeit at
different rates in the two mutation types. The commonality of the two mutation types might be particularly relevant to the asymptomatic stage of the condition, where the underlying Aβtoxicity has not yet resulted in further
pathological manifestations, such as intracerebral haemorrhages in Dutch MC, that might have flow on effects
leading to further differentiation in the disease process. Hence, we proceeded to group asymptomatic carriers of
PSEN1 and Dutch MC together for the below analysis of protein changes at the asymptomatic and symptomatic
stage of ADAD in order to give a larger sample number and thereby increase robustness.

Plasma protein profiles at asymptomatic and symptomatic stages of ADAD.

As expected, more
changes to the plasma protein profile were observed in sMC than in aMC when compared to NC, with only
seven proteins differing in abundance between aMC and NC, but 16 between sMC and NC. Evidence suggests
that biochemical changes in the periphery begin and are detectable very early in the disease process2,13. With
an average EYO of −8.5 for the aMC group, it is reasonable that we were able to detect some changes in the
plasma protein profile of asymptomatic participants, albeit less pronounced than in the sMC group. Except for
one protein (ATRN), the same proteins that were deregulated at the asymptomatic stage were also deregulated
at the later symptomatic stage, even though the aMC group included Dutch MC whereas the sMC group was
exclusively comprised of PSEN1 MC. These proteins in particular indicate an early and continuous involvement
of the immune system. By contrast, several proteins related to lipid metabolism were only differentially abundant
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in sMC, i.e. at a later stage of the disease. Therefore, alterations in lipid metabolism may be a later event in disease
progression relative to inflammation. Interestingly, many of the protein changes we observed also related to vascular health at both asymptomatic (PSEN1 and Dutch MC) and symptomatic stages (PSEN1 MC only), including
the apolipoproteins, AHSG, HRG, HCII and ACT. Cerebrovascular dysfunction is a common component in
LOAD pathology, where it may however be difficult to distinguish from comorbidity. In contrast, there is low
comorbidity of vascular disease in the younger ADAD population, strengthening our finding. Changes in the
cerebral blood flow of asymptomatic and mildly symptomatic PSEN1 and APP MC also indicate the presence of
cerebrovascular dysfunction early in the ADAD disease process19.
Although the individual proteins across studies do vary, the overall proteomic changes observed here with
regard to protein families were comparable to changes in CSF of ADAD subjects (mostly related to inflammation
and synaptic loss)11 and plasma from LOAD subjects20,21 (Supplementary Fig. S2). Sixteen of the 18 differentially abundant proteins identified here have previously been linked to LOAD (see below and22–25 for lumican,
ceruloplasmin and TBG). This adds to the increasing evidence from CSF biomarker, amyloid imaging and brain
volumetric studies that suggest the usefulness of ADAD as a model for LOAD2,4,5. Two proteins, ATRN and HCII,
have not previously been related to AD. ATRN differed significantly in the early stages of disease and showed a
strong positive association with glucose metabolism in the caudate nucleus. Its role in immunity, reactive oxygen
species (ROS) metabolism and CNS myelination could provide possible links to AD disease mechanisms via
inflammation, abnormal ROS metabolism in the brain and spongiform degeneration, which is sometimes associated with AD pathology26. HCII differed significantly and consistently in early and later stages of the disease and
was inversely associated with amyloid deposition in the caudate nucleus. It has been suggested as a biomarker for
arterial disease due to its role in atherosclerosis27–29. Hence, it might be indicative of the cerebrovascular component in AD pathology, which is evident in ADAD from an early stage19. More details on the individual differentially abundant proteins and their potential role in AD pathology are provided in the Supplementary Discussion,
classified by their main functions into inflammation, hemostasis/vascular health and lipid metabolism.

Proteins associated with cognition and neuroimaging biomarkers. Similar to the proteins whose
plasma levels were altered in aMC and sMC, the proteins that associated with any of the cognition or neuroimaging markers mainly have functions in the complement system (complement factors B and I, complement
components C2, C4-A, C6, and C8 β chain, complement C1R subcomponent, C4b-binding protein β chain
and C1 inhibitor), adaptive immunity (Ig γ-3 chain C region, Ig μchain C region), hemostasis/vascular health
(kininogen-1, α-2-antiplasmin, vitamin K-dependent protein S, C1 inhibitor, fibrinogen βchain, fibronectin,
C4b-binding protein βchain, haemoglobin subunit β, ApoA1, HCII, coagulation factor XII and HRG) and lipid
metabolism (ApoA1, ApoM, ApoE). ApoE, IgM and TBG, which associated in this study with glucose metabolism in the precuneus, in the caudate nucleus and amyloid deposition in the precuneus, respectively, were also
associated with grey matter changes in LOAD brains in a cross-sectional study25. In the AIBL cohort, plasma
ApoE levels were inversely associated with amyloid deposition measured by PiB PET30.
Nine of the proteins identified as differentially abundant in plasma were also associated with cognition or
neuroimaging markers (ApoA1, ApoM, HCII, HRG, C6, TBG, AHSG, ATRN, lumican). This overlap between
the different outcome measures supports the potential link of these proteins with AD pathology. In particular
proteins that associate with brain amyloid deposition, the hallmark feature of AD, might be of interest in future
studies. Here the strongest and most consistent associations were with C4A, tetranectin, kininogen-1, vitamin
K-dependent protein S, however, none of these proteins were detected at significantly different levels in the
plasma of NC, aMC and sMC. This could be due to method limitations, since the iTRAQ methodology is not particularly sensitive to minor changes. Hence these proteins, in particular C4A, which showed the most consistent
associations, might still be of interest in future studies and could be investigated with more sensitive quantitative
methods (e.g. ELISA). Protein associations with brain glucose metabolism (FDG PET), which is considered to
reflect neuronal damage, were less consistent than those with amyloid deposition.
Study limitations. Limitations to discovery ‘omics’ studies on blood in general are the relatively small num-

ber of proteins quantified compared to other approaches or sample types, which is due to the technical challenge
posed by the large dynamic range of proteins in blood. Furthermore, proteomics approaches generate data that
are quantitative only in a relative not absolute sense and often also insensitive to minor changes. Hence, proteomics in general should be regarded as a discovery tool to generate rather than confirm hypotheses. Thorough
follow up verification/validation of the quantitative changes observed is essential and should be carried out in
larger populations using targeted, rigorously quantitative approaches such as ELISA multiplex assays and mass
spectrometric based multiple reaction monitoring (MRM).
Limitations specific to this study include the small sample size and the relatedness of some individuals, which
was controlled for statistically using the GEE method with robust sandwich estimator. However, the robust sandwich estimator is known to perform poorly for small sample sizes, necessitating validation in a larger sample.
Furthermore, the quantitative changes observed between NC and aMC or sMC groups (Fig. 1) were statistically
significant, yet relatively small. In fact, the statistically significant difference between NC and MC groups detected
for HCII in the iTRAQ experiment could not be replicated using an orthogonal method (ELISA) despite the overall adequate correlation of data obtained by the two methods. This could be due to the small sample size, resulting
in a large effect of outliers, and/or quantitative differences between the HCII peptides and epitopes detected by
iTRAQ and antibody, respectively. This also illustrates that these proteins despite offering valuable insights into
pathways associated with ADAD and its progression might not have great potential as biomarkers. As pointed
out above for proteomics studies in general, further ELISA or MRM assays and a larger sample would be needed
to assess how well the changes we observed in this preliminary study replicate in a larger sample and whether
any of the proteins identified here are biomarker candidates. In addition, many of these proteins might lack the
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specificity required for a biomarker, since for example proteins related to inflammation would be expected to be
affected by a wide variety of conditions other than AD.
The strength of our study lies in its truly unbiased discovery approach, providing insights into what processes
are involved at certain stages of the disease. Moreover, the young age of this cohort excludes many of the age- and
comorbidity-associated confounders common to older LOAD cohorts. The inclusion of as yet asymptomatic
participants who are destined to develop AD later in life allows for identification of proteins associated with the
very early stages of the disease.

Conclusion

In summary, the proteomic changes in plasma from carriers of mutations causing ADAD are consistent with the
well-established role of inflammation and lipid metabolism in AD pathology. Changes related to inflammation
were evident early in asymptomatic individuals; however, changes related to lipid metabolism were only evident
at the later symptomatic stage of the disease. Interestingly, the changes also implied a vascular component even
at the asymptomatic stage in this young cohort. Cerebrovascular dysfunction is common in LOAD, where it is
however difficult to distinguish from a comorbidity in mostly elderly subjects. Because the younger age of the
ADAD population and low vascular comorbidity, our findings support a vascular and inflammation process in
AD. Due to increasing evidence supporting the usefulness of ADAD as a model for LOAD, we believe the proteins
identified here might also be associated with the asymptomatic or prodromal stages of LOAD.

Materials and Methods

Study population and blood collection.

EDTA plasma samples were obtained from 35 participants of
the Dominantly Inherited Alzheimer Network (DIAN) performance sites at the Edith Cowan University, Perth,
and the University of Melbourne, Melbourne, Australia. DIAN is an ongoing global, collaborative effort of international AD centres that uses standardised protocols to obtain longitudinal clinical, cognitive, genetic, neuroimaging, biofluid and neuropathological data from asymptomatic and symptomatic MC and their NC family
members31. Adult children (18 years or older) of parents clinically affected by ADAD are eligible for enrolment
in DIAN. In May 2012, the DIAN cohort numbered 255 individuals31. Ethics approval was provided by the ethics committees of the Hollywood Private Hospital (WA), Edith Cowan University, the University of Western
Australia and the Melbourne Health Human Research Ethics Committee. All experiments and methods were
carried out in accordance with the approved guidelines and regulations. All participants, or, in cases of impaired
capacity to give consent, their proxies, gave written informed consent before their participation.
Protocols for DIAN blood collection and processing are consistent with the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) protocols32. Blood was collected into EDTA-coated polypropylene tubes by venepuncture in the
morning after overnight fasting. EDTA plasma samples were stored at −80 °C in small volume aliquots to limit
the number of freeze/thaw cycles to a maximum of two.
To determine the parental AAO, family members were asked in a semi-structured interview to estimate the
age at which the parent’s progressive cognitive decline became evident. The EYO calculated as the age of the participant at time of blood draw minus the parental AAO.

Sample preparation, iTRAQ-labelling and LC-MSMS.

The six most abundant plasma proteins (albumin, transferrin, immunoglobulins G and A, haptoglobin and antitrypsin) were immunodepleted from plasma
samples (20 μl) using the Agilent (Santa Clara, USA) Multiple Affinity Removal System Hu6 column and buffer
kit on a HP 1090 HPLC system (Agilent, Santa Clara, USA) according to manufacturer’s instructions. We previously verified by mass spectrometric analysis that this method consistently removes the six targeted proteins
only20. Here we analyzed unfractionated plasma and high and low abundance protein fractions from four participants by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE) (NuPAGE 4–12% gradient
Bis-Tris gels, Life Technologies, Carlsbad, USA) to again verify consistent depletion of the six most abundant
proteins across samples (Supplementary Fig. S3). All low abundance protein fractions were buffer exchanged and
also analyzed by SDS PAGE (NuPAGE 4–12% gradient Bis-Tris gels, Life Technologies, Carlsbad, USA) prior to
tryptic digest and labeling with iTRAQ reagents (Supplementary Fig. S4). For a reference to be included in all
multiplex runs, 12 μl plasma each from all NC were pooled, then immunodepleted and prepared as the other
samples. Samples were stored at −80 °C until further use.
Labelling of tryptic peptides with iTRAQ 8-plex reagents (Sciex, Framingham, USA) was carried out according to manufacturer’s instructions with slight modifications as outlined in Muenchhoff, et al.20. iTRAQ-labelled
peptides were analysed by LC-MSMS on a LC Packings capillary HPLC system (Thermo Scientific Dionex,
Waltham, USA) connected to a TripleTOF 5600+ hybrid tandem mass spectrometer (ABSciex, Foster City, USA).
Further details on the method are provided in the Supplementary Methods.

Protein identification and quantitation. LC-MSMS data were processed with Protein Pilot v4.0
(ABSciex, Foster City, USA), applying bias and background correction, and searched against the Swiss-Prot Homo
sapiens complete proteome to which a list of common contaminant proteins (provided with the Protein Pilot
v4.0 software) was added. False discovery rate (FDR) analysis was performed by Protein Pilot v4.0. For statistical
analyses, the technical duplicates were processed together in Protein Pilot v4.0 and the protein summaries for the
six iTRAQ runs were exported into Excel. The summaries were collated, omitting proteins below 1% FDR, with
less than two distinct peptides for identification, from non-human origin (e.g. bovine serum albumin and porcine
trypsin contaminants), or without quantitation results.
Enzyme-linked immunosorbent assay for quantitation of heparin cofactor II. HCII was quantified in the low abundance protein fractions derived from plasma samples using a commercially available ELISA
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kit (catalogue no. ELH-SERPIND1, RayBiotech, Norcross, USA) according to manufacturer’s instructions. For
the assay, all low abundance protein fractions were diluted to 0.4 μg/ml. Samples were assayed in duplicate and
the average intra-assay coefficient of variation was 2.7%.

Neuropsychological testing.

Cognitive status was measured using the Clinical Dementia Rating
(CDR)33,34. The CDR scale is widely used in dementia research. Scores of 0, 0.5, 1, 2 and 3 denote no cognitive
impairment, very mild, mild, moderate and severe dementia, respectively. In DIAN, asymptomatic MC (aMC) are
defined by a CDR score of 0, whereas symptomatic MC (sMC) have a CDR score of ≥0.5. Participants also underwent the Mini Mental State Exam (MMSE), a measure of general cognitive function with scores ranging from 0
(severe impairment) to 30 (no impairment). Scores of ≥24 indicate normal cognitive function35. For measures
of episodic memory, participants were tested using Logical Memory IA – Immediate Recall (LM-IA) and Logical
Memory IIA – Delayed Recall (LM-IIA) from the Wechsler Memory Scale – Revised36.

Neuroimaging.

Brain imaging was performed according to ADNI protocols32. Details on how Pittsburgh
compound B (PiB) and fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging were performed are given in the supplementary information of Bateman et al.2.

Statistical analyses.

Generalized estimating equations (GEE) method was used to analyse the correlated
samples within the six families37. Each family was designated as a cluster, resulting in six clusters with sizes of
2, 1, 3, 4, 19 and 6 participants each. We used a linear model with age, gender, APOE ε4 status, mutation status and
EYO as covariates and the continuous dependent variables were z-transformed. The R geepack (version 1.2-0)38,39
was used to fit the GEE with exchangeable covariance structure and robust sandwich standard error for the
parameter estimates with Gaussian and binomial families respectively for continuous and binary dependent variables. For multiple comparison correction, the false discovery adjusted p-values (q-values) were obtained using
the bioconductor R package qvalue (version 1.34.0)40 with default parameter and method41. Whenever the global
test is significant, a pairwise comparison under the GEE general linear model was done by comparing the base
line category with other groups.

Protein network and pathway analysis.

The list of 18 proteins that were differentially abundant in NC
and MC at asymptomatic and symptomatic stages was submitted to the web-based bioinformatic tool STRING
v9.142 for enrichment analysis against the background of the 81 proteins quantified in all iTRAQ experiments. A
network analysis of the 18 proteins was performed using the Core Analysis tool of QIAGEN’s Ingenuity Pathway
Analysis (IPA, QIAGEN Redwood City, USA, www.qiagen.com/ingenuity).

References

1. Wimo, A. & Prince, M. World Alzheimer Report 2010: The Global Economic Impact of Dementia. (Alzheimer’s Disease International,
2010).
2. Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 367, 795–804 (2012).
3. Ryman, D. C. et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 83,
253–260 (2014).
4. Reiman, E. M. et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer’s
disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol 11, 1048–1056 (2012).
5. Thomas, J. B. et al. Functional connectivity in autosomal dominant and late-onset Alzheimer disease. JAMA Neurol 71, 1111–1122
(2014).
6. Crehan, H., Hardy, J. & Pocock, J. Microglia, Alzheimer’s disease, and complement. Int J Alzheimers Dis 2012, 983640 (2012).
7. Mapstone, M. et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 20, 415–418 (2014).
8. Kiddle, S. J. et al. Candidate blood proteome markers of Alzheimer’s disease onset and progression: a systematic review and
replication study. J Alzheimers Dis 38, 515–531 (2014).
9. Sattlecker, M. et al. Alzheimer’s disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimers Dement
10, 724–734 (2014).
10. Fortea, J. et al. Cerebrospinal fluid biomarkers in Alzheimer’s disease families with PSEN1 mutations. Neurodegener Dis 8, 202–207
(2011).
11. Ringman, J. M. et al. Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer
disease mutations. Arch Neurol 69, 96–104 (2012).
12. Wallon, D. et al. The French series of autosomal dominant early onset Alzheimer’s disease cases: mutation spectrum and
cerebrospinal fluid biomarkers. J Alzheimers Dis 30, 847–856 (2012).
13. Fagan, A. M. et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer’s disease. Sci Transl Med 6, 226–230
(2014).
14. Bateman, R. J. et al. Autosomal-dominant Alzheimer’s disease: a review and proposal for the prevention of Alzheimer’s disease.
Alzheimers Res Ther 3, 1–13 (2011).
15. Kamp, J. A. et al. Amyloid beta in hereditary cerebral hemorrhage with amyloidosis-Dutch type. Rev Neurosci 25, 641–651 (2014).
16. Rau, J. C., Beaulieu, L. M., Huntington, J. A. & Church, F. C. Serpins in thrombosis, hemostasis and fibrinolysis. J Thromb Haemost
5 Suppl 1, 102–115 (2007).
17. Tolosano, E., Fagoonee, S., Morello, N., Vinchi, F. & Fiorito, V. Heme scavenging and the other facets of hemopexin. Antioxid Redox
Signal 12, 305–320 (2010).
18. Hu, C. A., Klopfer, E. I. & Ray, P. E. Human apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease. FEBS Lett 586,
947–955 (2012).
19. McDade, E. et al. Cerebral perfusion alterations and cerebral amyloid in autosomal dominant Alzheimer disease. Neurology 83,
710–717 (2014).
20. Muenchhoff, J. et al. Plasma protein profiling of mild cognitive impairment and Alzheimer’s disease across two independent cohorts.
J Alzheimers Dis 43, 1355–1373 (2015).
21. Song, F. et al. Plasma protein profiling of Mild Cognitive Impairment and Alzheimer’s disease using iTRAQ quantitative proteomics.
Proteome Sci 12, 5 (2014).
22. Cutler, P. et al. Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: Two
novel biomarkers of Alzheimer’s disease in human plasma. Proteomics Clin Appl 2, 467–477 (2008).

Scientific Reports | 6:29078 | DOI: 10.1038/srep29078

10

www.nature.com/scientificreports/
23. Rembach, A. et al. Longitudinal Analysis of Serum Copper and Ceruloplasmin in Alzheimer’s Disease. J Alzheimers Dis 34, 171–182
(2013).
24. O’Bryant, S. E. et al. Biomarkers of Alzheimer’s disease among Mexican Americans. J Alzheimers Dis 34, 841–849 (2013).
25. Nazeri, A. et al. Imaging proteomics for diagnosis, monitoring and prediction of Alzheimer’s disease. Neuroimage 102 Pt 2, 657–665
(2014).
26. Whatley, B. R., Li, L. & Chin, L. S. The ubiquitin-proteasome system in spongiform degenerative disorders. Biochim Biophys Acta
1782, 700–712 (2008).
27. Huang, S. S. et al. Plasma heparin cofactor II activity is an independent predictor of future cardiovascular events in patients after
acute myocardial infarction. Coron Artery Dis 19, 597–602 (2008).
28. Ikeda, Y. et al. Heparin cofactor II, a serine protease inhibitor, promotes angiogenesis via activation of the AMP-activated protein
kinase-endothelial nitric-oxide synthase signaling pathway. J Biol Chem 287, 34256–34263 (2012).
29. Aihara, K., Azuma, H., Akaike, M., Sata, M. & Matsumoto, T. Heparin cofactor II as a novel vascular protective factor against
atherosclerosis. J Atheroscler Thromb 16, 523–531 (2009).
30. Gupta, V. B. et al. Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology 76, 1091–1098 (2011).
31. Morris, J. C. et al. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin
Investig 2, 975–984 (2012).
32. Mueller, S. G. et al. The Alzheimer’s disease neuroimaging initiative. Neuroimaging Clin N Am 15, 869–877 (2005).
33. Mckhann, G. et al. Clinical-Diagnosis of Alzheimers-Disease - Report of the Nincds-Adrda Work Group under the Auspices of
Department-of-Health-and-Human-Services Task-Force on Alzheimers-Disease. Neurology 34, 939–944 (1984).
34. Morris, J. C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43, 2412–2414 (1993).
35. Crum, R. M., Anthony, J. C., Bassett, S. S. & Folstein, M. F. Population-based norms for the Mini-Mental State Examination by age
and educational level. JAMA 269, 2386–2391 (1993).
36. Wechsler, D. Manual: Wechsler Memory Scale - Revised. (Psychological Corporation, 1987).
37. Burton, P., Gurrin, L. & Sly, P. Extending the simple linear regression model to account for correlated responses: An introduction to
generalized estimating equations and multi-level mixed modelling. Stat Med 17, 1261–1291 (1998).
38. Halekoh, U., Hojsgaard, S. & Yan, J. The R Package geepack for Generalized Estimating Equations. J Stat Softw 15, 1–11 (2006).
39. Yan, J. & Fine, J. Estimating equations for association structures. Stat Med 23, 859–874 (2004).
40. Dabney, A. & Storey, J. D. qvalue: Q-value estimation for false discovery rate control. R package version 1.34.0.
41. Storey, J. D. & Tibshirani, R. Statistical significance for genome-wide experiments. Proc Natl Acad Sci USA 100, 9440–9445 (2003).
42. Franceschini, A. et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids
Res 41, D808–815 (2013).

Acknowledgements

The authors would like to thank all participants in the DIAN and the Research Team. This work was facilitated
by the National Institute of Ageing grant UF1 AG032438, JC Morris, PI; Australian National Health and Medical
Research Council Program Grant 350833, Capacity Building Grant 568940, the Australian Research Council
Discovery Project Grant DP120102078 and the Rebecca L. Cooper Medical Research Foundation. The financial
support of these organizations is gratefully acknowledged.

Author Contributions

P.S.S. conceptualised the study. J.M. and A.P. were responsible for experimental design, data acquisition and initial
interpretation. J.M. wrote the first draft with help of A.P. and P.S.S. A.T. was responsible for statistical analysis.
M.R. facilitated data acquisition. V.B.G., P.C., C.L.M., J.C.M., R.J.B., A.M.F. and R.N.M. provided samples and
participant data and critically reviewed the manuscript. All authors reviewed the manuscript.

Additional Information

Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: Dr. Bateman received research grants from Pharma Consortium (Biogen
Idec, Elan Pharmaceuticals Inc., Eli Lilly and Co., Hoffman La-Roche Inc., Genentech Inc., Janssen Alzheimer
Immunotherapy, Mithridion Inc., Novartis Pharma AG, Pfizer Biotherapeutics R and D, Sanofi-Aventi, Eisai)
and is co-founder and part-owner of C2N. There are no conflicts relevant to this manuscript. Dr. Fagan is
a member of the scientific advisory boards of IBL International and Roche and is a consultant for AbbVie,
Novartis and DiamiR. There are no conflicts relevant to this manuscript. The other authors declare no potential
conflict of interest.
How to cite this article: Muenchhoff, J. et al. Changes in the plasma proteome at asymptomatic and
symptomatic stages of autosomal dominant Alzheimer’s disease. Sci. Rep. 6, 29078; doi: 10.1038/srep29078
(2016).
This work is licensed under a Creative Commons Attribution 4.0 International License. The images
or other third party material in this article are included in the article’s Creative Commons license,
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this
license, visit http://creativecommons.org/licenses/by/4.0/

Scientific Reports | 6:29078 | DOI: 10.1038/srep29078

11

